Novel treatment approaches and pediatric research networks in status epilepticus

  • Meir Bialer*
  • , Helen Cross
  • , Ulrike B.S. Hedrich
  • , Lieven Lagae
  • , Holger Lerche
  • , Tobias Loddenkemper
  • *Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

3 Scopus citations

Abstract

This paper contains five contributions which were presented as part of the novel therapies section of the 7th London-Innsbruck Colloquium on Status Epilepticus and Acute Seizures. These illustrate recent advances being made in the management and therapy of status epilepticus. The five contributions concern: genetic variations in Na + channel genes and their importance in status epilepticus; the European Reference Network for rare and complex epilepsies EpiCARE; the North American Pediatric Status Epilepticus Research Group (pSERG); Fenfluramine as a potential therapy for status epilepticus’ and the valproate derivatives, valnoctamide and sec-butylpropylacetamide (SPD), as potential therapies for status epilepticus.

Original languageEnglish
Article number106564
JournalEpilepsy and Behavior
Volume101
DOIs
StatePublished - Dec 2019

Bibliographical note

Publisher Copyright:
© 2019 Elsevier Inc.

Fingerprint

Dive into the research topics of 'Novel treatment approaches and pediatric research networks in status epilepticus'. Together they form a unique fingerprint.

Cite this